INDEX
ABOUT JUNSHI
THERAPEUTIC AREAS
PRESS RELEASES
CAREERS
INVESTORS
CONTACT
Entrance
中文简体
中文繁体
EN
Menu
INDEX
ABOUT JUNSHI
THERAPEUTIC AREAS
PRESS RELEASES
CAREERS
INVESTORS
CONTACT
中文简体
中文繁体
EN
PRESS RELEASES
NMPA Approves Toripalimab's Second Indication in China
02-19
2021
NMPA Accepted sNDA for Toripalimab for The 1st-Line Treatment of NPC
02-18
2021
FDA Grants Toripalimab Fast Track Designation for Mucosal Melanoma
01-22
2021
Junshi Biosciences Announces Acceptance by NMPA of its IND Application for JS006
11-26
2020
More
Back
List
